World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
105
Citations
49816
World Ranking
6696
National Ranking
3536

Andrew D. Zelenetz publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Andrew D. Zelenetz sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 725 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Andrew D. Zelenetz D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew D. Zelenetz sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 105 D-Index — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Andrew D. Zelenetz is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research activity is centered primarily within the field of Medicine, encompassing 481 publications. The subfields of study most represented in their work include Pathology and Forensic Medicine, Genetics, Oncology, Pulmonary and Respiratory Medicine, and Molecular Biology.

The main topics addressed in their research focus on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, and CAR-T cell therapy research. Other areas of work include Viral-associated cancers and disorders, CNS Lymphoma Diagnosis and Treatment, Lung Cancer Treatments and Mutations, and Ovarian cancer diagnosis and treatment.

Frequent co-authors collaborating with Andrew D. Zelenetz include Gilles Salles, Paul A. Hamlin, Ariela Noy, Anita Kumar, and Lorenzo Falchi. These collaborations signify ongoing teamwork in related research domains.

The scientist has published extensively in a range of medical and oncological journals. The most frequent publication venues are Blood, Hematological Oncology, Journal of Clinical Oncology, Blood Advances, and Leukemia & lymphoma/Leukemia and lymphoma.

Some recent papers authored or co-authored by Andrew D. Zelenetz include:

  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee (2022, Blood)
  • Outcomes of COVID-19 in patients with CLL: a multicenter international experience (2020, Blood)
  • Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups (2020, Blood Cancer Journal)
  • Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma (2021, Journal of Clinical Oncology)
  • NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021 (2021, Journal of the National Comprehensive Cancer Network)

Best Publications

  • The 2016 revision of the World Health Organization classification of lymphoid neoplasms

    Steven H. Swerdlow;Elias Campo;Stefano A. Pileri;Nancy Lee Harris

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

    Roland Schmitz;George W. Wright;Da Wei Huang;Calvin A. Johnson

  • Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

    Kenneth R. Carson;Andrew M. Evens;Elizabeth A. Richey;Thomas M. Habermann

  • An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

    Zheng Zhou;Laurie H. Sehn;Alfred W. Rademaker;Leo I. Gordon

  • Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

    Carla Casulo;Michelle Byrtek;Keith L. Dawson;Xiaolei Zhou

  • Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

    Owen A. O'Connor;John Wright;Craig Moskowitz;Jamie Muzzy

  • Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas

    M. S. Kaminski;A. D. Zelenetz;O. W. Press;M. Saleh

  • Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

    Owen A. O'Connor;Mark L. Heaney;Lawrence Schwartz;Stacie Richardson

  • A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

    Craig H. Moskowitz;Stephen D. Nimer;Andrew D. Zelenetz;Tania Trippett

  • Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

    Tarun Kewalramani;Andrew D. Zelenetz;Stephen D. Nimer;Carol Portlock

  • Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

    Adam M Petrich;Mitul Gandhi;Borko Jovanovic;Jorge J Castillo

  • Non-Hodgkin's Lymphomas

    Andrew D. Zelenetz;Ranjana H. Advani;John C. Byrd;Myron S. Czuczman

  • Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

    Julie Marie Vose;Richard L. Wahl;Mansoor Saleh;Ama Z. Rohatiner

  • Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17).

    Jonathan D. Licht;Christine Chomienne;Andre Goy;Alex Chen

  • Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma

    Craig H. Moskowitz;Joseph R. Bertino;Jill R. Glassman;Eric E. Hedrick

  • NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

    Zelenetz Ad;Abramson Js;Advani Rh;Andreadis Cb

  • Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma

    Craig H. Moskowitz;Heiko Schöder;Julie Teruya-Feldstein;Camelia Sima

  • Follicular Lymphoma in the United States: First Report of the National LymphoCare Study

    Jonathan W. Friedberg;Michael D. Taylor;James R. Cerhan;Christopher R. Flowers

  • Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.

    David J. Straus;Carol S. Portlock;Jing Qin;Jane Myers

Frequent Co-Authors

Craig H. Moskowitz
Craig H. Moskowitz University of Miami
David J. Straus
David J. Straus Memorial Sloan Kettering Cancer Center
Joachim Yahalom
Joachim Yahalom Memorial Sloan Kettering Cancer Center
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Heiko Schöder
Heiko Schöder Memorial Sloan Kettering Cancer Center
Leo I. Gordon
Leo I. Gordon Northwestern University
Myron S. Czuczman
Myron S. Czuczman Citius Pharmaceuticals, Inc.
Julie M. Vose
Julie M. Vose University of Nebraska Medical Center
Ahmet Dogan
Ahmet Dogan Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine can open doors to a variety of related healthcare fields and professional pathways. Many students explore online degrees for flexibility and diverse options.

If you’re interested in shaping healthcare policies or managing medical facilities, a healthcare administration degree can provide the skills needed for leadership roles. For nurses aiming to advance their practice, there are adn to fnp bridge programs offering a streamlined transition from an Associate Degree in Nursing to becoming a Family Nurse Practitioner.

Nutrition is another vital field in healthcare. Pursuing an online bs in nutrition can pave the way for roles in wellness, preventive care, or dietetics. Those aspiring to executive positions in hospital or healthcare system management might consider cahme-accredited online mha programs, which are recognized for high standards in healthcare administration education.

Exploring these alternative degrees and career paths broadens options for students passionate about making a difference in healthcare beyond traditional medical school routes.

Best Scientists Citing Andrew D. Zelenetz

Trending Scientists

Recently Published Articles